by announcing an investigation, ADXS market caps drops 10%.. I would encourage ADXS management announce the counter suit against these bottom feeder to prevent these kind of easy money scams by the bottom feeder firms..
BTD means nothing unless the results are statistically significant improvement over the existing treatments. Rintega is a wash at this time because the FDA has told CLDX that the sample size was not met the FDA requirements NOR statistically significant. Stop beating a dead horse.
stop pumping.. drug got approved by an European country and stock up 2% after 50% dropped for the past 3 weeks. this is another over-valued and foooooked up biostock...
MA&TD never filed for the AA.. because FDA would rejected and reveal the real reason of a failed study.. MA&TD are deceptive about the way they blamed the FDA by saying “Ultimately ...the FDA's concern (is) that the results of the study could be induced by chance”. The fact of the matter that they never filed for the AA to be reviewed by the FDA.
if CLDX management, each get paid $1 / year, but get additional stock options for their compensation package.. their behavior would changed immediately.. simply because they have to focus on producing results like getting FDA approval or drugs to market quickly instead of producing nothing and still getting $1Mil payday.. if option is under water, so what?
why do they let their investments dropped 50% in 10 days w/o taking actions to deter short sellers and a handful of day traders? unless they're the one who marching out the exit doors.. CLDX management is as incompetent as it comes.. they don't even know the minimum sample size is required to get the FDA to review the clinical data..
CLDX keeps claiming the early results were statistical significant, but after a long wait, investors found out that sample size was a surprise.. the same old sheet with the 1135 clinical trial, recruiting effort were doing good until 6 months later to announce only 1 patient signed up for the clinical trial.. this is a foockng fraud.
bio aka Frankie, you're clueless.. there's another gap you need to fill is between your ears... LMAO
0users liked this postsusers disliked this posts2Reply
21.2 GAP FILL
by biospeculator20l4 • Jul 30, 2015 9:59 AM Flag
I BUY THERE
BIO BREAKING DOWN
CLDX BROKE 23.2 SUPPORT AND 200 DY
Now you know why insiders don't purchase their own stock.. Simply because they know it doesn't work as they claim in public..
if it works marginally, fda would have granted them conditional approval.. In this case, nada.. Nothing works.. They keep buying time, by saying next phase, next clinical trials, next readout.. Next sno, next asco, next ccs, chapter 11 is next..
pipeline of emptiness.. they promise to cure A-Z cancers, but they don't even know how to apply statistics to follow sample guidelines set by the FDA for their clinical trials.. it turns out CLDX is just another bio-scam..
normally it gaps up at the open, going down the rest of the day, and then closed RED..
if you want to own biotechs with covered call in mind, then you need to own with low volatility stocks like AMGN, BMY, MRK. Otherwise, I would suggest to buy debit call spreads and credit put spreads to minimize loss with maximum gains (don't buy both sides at the same time).. company like ADXS, CLLS, CLDX, JUNO, MGNX.. GL
this is robo-spam to scam investors..
it is easy to create an illusion for dumpassesssss... CLDX generates a lot of thunders, but not produce a single drop of rain... now they go all-in on waiting for ACT-IV data..
Looks like CLDX's CEO is sleeping at the wheel, why don't CLDX's CEO get the CBAR's requirements upfront wrt acceptable sample size, primary endpoint of the study, and the timelines for each milestones before signing up patients for the study. there will be more surprises in Q1-2016 and beyond..
"CBAR has guided us that the small sample size would be a potential concern for them if we were to file. While this was a surprise to us, we certainly are disappointed particularly for patients."
non-approved pipeline worths nothing.. a lot of thunders but no rain... stop dreaming.. CLDX is a $3 stock (cash value).. 25% drop tomorrow and this POS will be traded below $10 by the end of August.. keep pumpin'..
$21.50 is already priced in the Rintega approval.. fundamentally, this is a $3 stock.. the first drug will be approved in 2014, mid-year 2015, maybe 2016, should be 2017, guaranteed 2018..etc.. pick any year and #$%$ your way through it... none of the drug works, can't prove any statistical significant to existing drugs, no company wants to buy drugs that are as effective as a placebo.
what are they going to do with the newly CCO now eh, no drug on the market to sell?